- Home
- NCTY vs PLRX Comparison
NCTY vs PLRX Comparison
Compare NCTY & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 73.7M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCTY | PLRX |
|---|---|---|
| Price | $4.70 | $1.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 279.4K | ★ 362.2K |
| Earning Date | 03-27-2015 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.14 | $1.02 |
| 52 Week High | $11.60 | $1.95 |
Technical Indicators
Market Signals| Indicator | NCTY | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 56.96 |
| Support Level | $3.27 | $1.12 |
| Resistance Level | $5.62 | $1.26 |
| Average True Range (ATR) | 0.76 | 0.05 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 28.97 | 64.29 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.